Quality of Life of Patients Receiving Long-Term Treatment with First-Line Multiple Sclerosis Disease-Modifying Drugs: Results of a Russian Multicenter Study Using the MusiQol Questionnaire

We present here the results of a multicenter study addressing quality of life (QoL) using the MusiQoL questionnaire in 534 patients with multiple sclerosis receiving glatiramer acetate (GA) at a dose of 20 mg/day s.c. for 12 months. These data were compared with results from multicenter observations...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology 2015-03, Vol.45 (3), p.342-347
Main Authors: Boiko, O. V., Popova, E. V., Boiko, A. N.
Format: Article
Language:English
Subjects:
Activities of daily living
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Disease
Drug dosages
Health care
Multiple sclerosis
Neurobiology
Neurology
Neurosciences
Neurosurgery
Quality of life
Questionnaires
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present here the results of a multicenter study addressing quality of life (QoL) using the MusiQoL questionnaire in 534 patients with multiple sclerosis receiving glatiramer acetate (GA) at a dose of 20 mg/day s.c. for 12 months. These data were compared with results from multicenter observations using the same questionnaire in 1420 MS patients receiving s.c. β-interferon-1a at a dose of 44 μg three times a week for at least one year. QoL measures were found to depend on gender, age, and duration of MS. Statistically significant improvements in QoL were seen at 12 months of treatment on the background of courses of GA. Treatment with β-interferon-1a produced improvements by 6 months.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-015-0078-8